PharmaJet CEO featured in CEOCFO Magazine

GOLDEN, Colo. — February 1, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that Chris Cappello, President and CEO of PharmaJet was featured in CEOCFO Magazine.

The interview focused on how the Needle-free technology works, PharmaJet’s partnerships with pharmaceutical companies, and how the Colorado-based company is scaling production to meet increased customer demand.

University of Cambridge begins COVID-19 Clinical Trial Using PharmaJet’s Needle-free System

GOLDEN, Colo. — January 18, 2022 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System (NFIS) will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK, recently announced the start of the Phase 1 clinical trial.

PharmaJet partner Zydus Cadila announces COVID-19 vaccine expansion plan to multiple countries with Korean firm

GOLDEN, Colo. — January 4, 2022 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D®) in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval (EUA) by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income countries in Latin America and Asian New Southern Policy member countries. It is exclusively delivered by the PharmaJet Tropis® Needle-free Injection System.

PharmaJet partner, Nykode Therapeutics announces phase 1/2 clinical trial with next generation DNA-based COVID-19 vaccine candidates

GOLDEN, Colo. — December 14, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that one of its pharmaceutical partners, Nykode Therapeutics (formerly Vaccibody) has begun a phase 1/2 clinical trial to specifically address emerging SARS-CoV-2 variants. The DNA-based vaccines will be delivered intramuscularly in the clinical trial exclusively using the PharmaJet Stratis® Needle-free Injection System.

PharmaJet Named Asia’s Most Innovative Vaccine Delivery System at the Vaccine World Asia Congress 2021

GOLDEN, Colo. — November 30, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, has been named “Asia’s Most Innovative Vaccine Delivery System” at the Asia-Pacific Vaccine Excellence Awards 2021 (AVEA 2021). The award was accepted by Paul LaBarre, MS, MBA, Vice President, Global Business Development, PharmaJet, Inc.

PharmaJet Presents How to Improve Vaccine Performance with Needle-free Delivery at Vaccine World Asia Congress

GOLDEN, Colo. — November 15, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the Vaccine World Asia Congress 2021 on November 17. The presentation, entitled Improving Vaccine Performance with Needle-free Delivery, is being presented by Paul LaBarre, MS, MBA, Vice President, Global Business Development.

PharmaJet , WHO and BMGF conduct Somalia Polio Vaccination Campaign

GOLDEN, Colo. — October 21, 2021 - PharmaJet® the maker of innovative, needle-free injection technology, today announced that its Tropis® intradermal needle-free injection system is being used in a campaign in Somalia delivering inactivated polio vaccine to more than 110,000 children. The purpose of the campaign, funded in part by the Bill and Melinda Gates Foundation, using PharmaJet’s needle-free delivery product, supplied by the World Health Organization (WHO), is to ensure children under 5 who missed their routine immunization, receive their full regimen of inactivated polio vaccine.

PharmaJet Presents Needle-free delivery of COVID-19 Vaccines and Beyond at World Vaccine Congress – Europe

GOLDEN, Colo. — October 12, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, announced that their latest partnerships and research results will be presented at the World Vaccine Congress - Europe on October 21. The presentation, entitled Needle-free Delivery: COVID-19 Vaccines and Beyond, is being presented by Erin K. Spiegel, PhD, Vice President, Clinical & Regulatory Affairs at PharmaJet, Inc.

PharmaJet partner Zydus Cadila announces Emergency Use Authorization approval for world’s first plasmid DNA COVID-19 vaccine

GOLDEN, Colo. — August 23, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. The vaccine, ZyCoV-D, is exclusively administered using the PharmaJet Tropis® Needle-free Injection System.